615 related articles for article (PubMed ID: 17050367)
1. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
[TBL] [Abstract][Full Text] [Related]
2. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
[TBL] [Abstract][Full Text] [Related]
3. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging.
Hakyemez B; Erdogan C; Ercan I; Ergin N; Uysal S; Atahan S
Clin Radiol; 2005 Apr; 60(4):493-502. PubMed ID: 15767107
[TBL] [Abstract][Full Text] [Related]
4. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
Fayed N; Dávila J; Medrano J; Olmos S
Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative dynamic susceptibility contrast weighted magnetic resonance imaging (iDSC-MRI) - Technical considerations and feasibility.
Ulmer S; Helle M; Jansen O; Mehdorn HM; Nabavi A
Neuroimage; 2009 Mar; 45(1):38-43. PubMed ID: 19100843
[TBL] [Abstract][Full Text] [Related]
6. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
Law M; Oh S; Johnson G; Babb JS; Zagzag D; Golfinos J; Kelly PJ
Neurosurgery; 2006 Jun; 58(6):1099-107; discussion 1099-107. PubMed ID: 16723889
[TBL] [Abstract][Full Text] [Related]
7. Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results.
Di Costanzo A; Trojsi F; Giannatempo GM; Vuolo L; Popolizio T; Catapano D; Bonavita S; d'Angelo VA; Tedeschi G; Scarabino T
J Exp Clin Cancer Res; 2006 Sep; 25(3):383-90. PubMed ID: 17167979
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative dynamic susceptibility contrast MRI (iDSC-MRI) is as reliable as preoperatively acquired perfusion mapping.
Ulmer S; Hartwigsen G; Riedel C; Jansen O; Mehdorn HM; Nabavi A
Neuroimage; 2010 Feb; 49(3):2158-62. PubMed ID: 19900562
[TBL] [Abstract][Full Text] [Related]
9. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
Pirzkall A; Li X; Oh J; Chang S; Berger MS; Larson DA; Verhey LJ; Dillon WP; Nelson SJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):126-37. PubMed ID: 15093908
[TBL] [Abstract][Full Text] [Related]
10. A Magnetic Resonance comparative study between enhancement, rCBV and ACD in brain glioblastomas.
Aprile I; Muti M; Principi M; Bartolini N; Zenoni A; Tazza G; Italiani M; Ottaviano P
Radiol Med; 2002; 104(1-2):87-91. PubMed ID: 12386559
[TBL] [Abstract][Full Text] [Related]
11. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
Thomsen H; Steffensen E; Larsson EM
Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
[TBL] [Abstract][Full Text] [Related]
12. Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas.
Young R; Babb J; Law M; Pollack E; Johnson G
J Magn Reson Imaging; 2007 Oct; 26(4):1053-63. PubMed ID: 17896374
[TBL] [Abstract][Full Text] [Related]
13. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results.
Sadeghi N; Salmon I; Tang BN; Denolin V; Levivier M; Wikler D; Rorive S; Balériaux D; Metens T; Goldman S
J Magn Reson Imaging; 2006 Nov; 24(5):989-94. PubMed ID: 17031832
[TBL] [Abstract][Full Text] [Related]
14. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction.
Gasparetto EL; Pawlak MA; Patel SH; Huse J; Woo JH; Krejza J; Rosenfeld MR; O'Rourke DM; Lustig R; Melhem ER; Wolf RL
Radiology; 2009 Mar; 250(3):887-96. PubMed ID: 19244052
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
[TBL] [Abstract][Full Text] [Related]
16. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
[TBL] [Abstract][Full Text] [Related]
17. Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases.
Floeth FW; Wittsack HJ; Engelbrecht V; Weber F
Zentralbl Neurochir; 2002; 63(1):23-8. PubMed ID: 12098080
[TBL] [Abstract][Full Text] [Related]
18. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of dynamic contrast-enhanced perfusion with diffusion tensor imaging metrics in assessment of corticospinal tract infiltration in malignant glioma.
Awasthi R; Verma SK; Haris M; Singh A; Behari S; Jaiswal AK; Rajput D; Pandey R; Rathore RK; Pandey CM; Gupta RK
J Comput Assist Tomogr; 2010 Jan; 34(1):82-8. PubMed ID: 20118727
[TBL] [Abstract][Full Text] [Related]
20. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.
Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS
Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
